

Excellent Presentations at JSCO2013

Followings are the Excellent Presentations selected by the Program Committee from those presented at the 51st Annual Meeting of the Japan Society of Clinical Oncology (JSCO2013).

Number of presentations awarded the Excellent Presentations

79 (including 10 Best Presentations)

Head and neck cancer

- Expression of stem cell markers Oct3/4 and Nanog and its clinical significance in oral tongue squamous cell carcinoma
Noboru Habu (Keio University; National Tokyo Medical center; Tachikawa Hospital)
- Chemoradiotherapy for oropharyngeal cancer: retrospective observational study by multi-institution
Satoshi Kano (Hokkaido University)

Oral cancer

- A retrospective multicenter study on prognosis of oral squamous cell carcinoma patients with regional lymph node metastasis
Souichi YANAMOTO (Nagasaki University)

Breast cancer

- Subtype specific chromosomal aberrations in breast cancer

Eriko Tokunaga (Kyushu University)

- MRI-guided quadrantectomy in patients with nonfocal ductal carcinoma in situ of the breast

Masahiro Sakakibara (Chiba University)

- Different impact on prognosis according to residual tumor status after neoadjuvant chemotherapy in breast cancer subtypes

Noriaki Wada (National Cancer Center Hospital East)

- Ph III BOLERO-2 study of everolimus plus exemestane: Japanese subgroup analysis **【Best Presentation】**

Norikazu Masuda (Osaka National Hospital)

- Comparative effectiveness of neoadjuvant therapy for HER2 (+) breast cancer

Tetsu Hayashida (Keio University)

- A Phase 1b Trial of Trastuzumab Emtansine in Combination with Pertuzumab

Hiroji Iwata (Aichi Cancer Center)

- Safety of trastuzumab emtansine in patients with HER2-positive metastatic breast cancer

Hiroyoshi Doihara (Okayama Univ. Hospital)

- Prognostic significance of progesterone receptor expression and its appropriate cutoff value in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer

S Kurozumi (Saitama Cancer Center)

- A prospective multi-institutional feasibility study of accelerated partial breast irradiation (APBI) using interstitial brachytherapy. Results of the secondary endpoints at 30 months

Ken Yoshida (Osaka medical college)

- Efficacy of zoledronic acid in postmenopausal women with adjuvant letrozole

Norio Kohno (Tokyo Medical Univ. Hospital)

Lung cancer

- A prospective study of carboplatin and paclitaxel for advanced thymic carcinoma

Akira Ono (Shizuoka Cancer Center)

- Phase II Study of Docetaxel and CBDCA Plus Bevacizumab for Non-squamous NSCLC

Kozo Yoshimori (Fukujuji Hosp)

- Identification of RET and ROS tyrosine kinase fusions in lung adenocarcinomas and phase II trial of the RET inhibitor cabozantinib (XL184) **【Best Presentation】**

Yoshiyuki Suehara (Memorial Sloan-Kettering Cancer Center)

- Biomarker analysis of WJOG4107 (A randomized phase II trial of adjuvant chemotherapy with S-1 versus CDDP+S-1 for resected stage II-IIIa non-small cell lung cancer (NSCLC))
Toshiaki Takahashi (West Japan Oncology Group)

Hepato-biliary-pancreatic cancers

- Liver resection for colorectal metastases in patients with concomitant extrahepatic disease **【Best Presentation】**
Kazunori Nojiri (Yokohama City University)
- A central surgical review of resectability of optimally-unresectable colorectal liver metastases following neoadjuvant chemotherapy (KSCC 0802)
Mitsuhsa Takatsuki (Nagasaki University)
- Interim analysis of a phase II trial of neoadjuvant chemoradiation therapy followed by conventional resection for cholangiocarcinoma
Y Katayose (Tohoku University)
- Oral S-1 with concurrent radiotherapy versus S-1 alone in patients with locally unresectable pancreatic cancer
H Shinchi (Kagoshima University)

- Phase 2 study of FOLFIRINOX as 1st-line therapy for metastatic pancreatic cancer.

Masafumi Ikeda (National Cancer Center Hospital East)

- Outcomes of Gemcitabine and Erlotinib for advanced pancreatic cancer in NCCHE

Akiko Kuwahara (National Cancer Center Hospital East)

- Implication of adjuvant surgery for unresectable pancreatic cancer

Fuyuhiko Motoi (Tohoku Univ. Hosp.)

Esophageal cancer

- Potential of FDG-PET on decision of treatment for esophageal cancer

Masanobu Nakajima (Dokkyo Medical University)

- Impact of sarcopenia and body weight loss during neoadjuvant chemotherapy the risk of postoperative infectious complications in patients with esophageal cancer **[Best Presentation]**

Tsutomu Hayashi (Tokai University)

- Tumor-suppressive effects and mechanism of efatutazone, a novel PPAR γ agonist in esophageal squamous cell carcinoma

Hiroshi Sawayama (Kumamoto University)

- A phase II trial of DCF-R in advanced esophageal cancer (KDOG 0501-P2)

Katsuhiko Higuchi (Kitasato University East Hospital)

- Detection of circulating tumor cells in patients with un-resectable esophageal squamous cell carcinoma

Daisuke Matsushita (Kagoshima University)

- Preliminary results of proton therapy combined with concurrent chemotherapy for squamous cell carcinoma of the esophagus

Hitoshi Ishikawa (University of Tsukuba)

Gastric cancer

- Inhibition of paclitaxel by α 1-acid glycoprotein and biochemical modulation

Yoshinao Ohbatake (Kanazawa Univ.)

- Randomized phase III trial of irinotecan plus cisplatin versus irinotecan in patients with metastatic gastric cancer resistant to S-1 monotherapy: Survival analysis

Shinya Tokunaga (Osaka City General Hospital)

- A feasibility study of docetaxel, cisplatin and S-1-Trastuzumab (DCS-T) chemotherapy for HER2 positive unresectable gastric cancer **【Best Presentation】**

Yasushi Sato (Sapporo Med. Univ.)

- A phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis

Hironori Yamaguchi (The University of Tokyo)

- HER2 status of advanced or recurrent gastric cancer - Prospective cohort study

JFMC44-1101

Toshihiko Tomita (Hyogo College of Medicine)

- Analysis of gene mutations in KRAS, NRAS, BRAF and PIK3CA in patients who received systemic chemotherapy with metastatic gastric cancer.

Masaru Fukahori (National Cancer Center Hospital)

- Development and Validation of Gastric Cancer New Nomogram based on Preoperative Clinical Prognostic Factors

Etsuro Bando (Shizuoka Cancer Center)

- Randomized phase II study of 6 vs. 12 months of adjuvant imatinib for GIST patients.

Junya Fujita (NTT West Osaka Hospital)

- Phase III of regorafenib in pretreated advanced GIST: Japanese sub-analysis

Toshihiko Doi (National Cancer Center Hospital East)

Colorectal cancer

- Prognostic significance of the DICER1 mRNA expression in colorectal cancer

Hisae Iinuma (Teikyo Univ.)

- Strategy for cStage4 colorectal cancer: Should treat in either of Chemotherapy or resection of primary tumor?

Shigeyoshi Iwamoto (Kansai Medical University)

- A questionnaire on QOL and toxicity in colorectal cancer survivors received adjuvant chemotherapy.

Hiroya Taniguchi (Aichi Cancer Center Hospital)

- Relationship between prognosis and nutrition in patients with unresectable CRC

Yasuo Sakamoto (Kumamoto University)

- Cohort study of 1st line chemotherapy for metastatic colorectal cancer (EMERaLD)

Hiroshi Matsuoka (Fujita Healthy University)

- Comparison of the efficacy of IRIS and IRIS/Bev: analysis of two phase II trials

Kazuteru Hatanaka (Hakodate Municipal Hospital)

- Adjuvant therapy in elderly colon cancer patients: subgroup analysis of ACTS-CC

trial **【Best Presentation】**

Megumi Ishiguro (Tokyo Medical and Dental University)

- Effectiveness of preoperative chemoradiotherapy for rectal cancer according to stem cell marker expression

Eiji Shinto (National Defense Medical College)

- Methylated miR-124, -137 and -34b/c as predictive biomarkers for ulcerative colitis-associated colorectal neoplasia

Yuji Toiyama (Mie University)

- Systemic siRNA delivery by 10nm carrier performed tumor-specific accumulation

Xin Wu (Osaka University)

Gynecologic cancers

- Prospective study of sentinel lymph node detection in patients with cervical cancer

Natsuki Tsuji (Kitano Hospital)

- P2 Study of two PI3K/mTOR Inhibitors in Patients with Endometrial Cancer - Japan

Lead-in-Cohort

Kei Muro (Aichi Cancer Center Hospital)

- A retrospective analysis of docetaxel-cisplatin therapy (DP therapy) for recurrent endometrial cancer

Tomomi Ninomiya (Keio University)

- Medroxy-progesterone-acetate (MPA) treatment for endometrial cancer and atypical endometrial hyperplasia in young patients

Yoshimichi Tanaka (Osaka Medical College)

- Review of the Risk reduction surgery for BRCA1 · BRCA2 gene mutations **[Best Presentation]**

Hanako Shimizu (Showa University)

- Favorable prognostic factors in the treatment of stage IV ovarian cancer

Junzo Hamanishi (Kyoto University)

Prostate and testicular cancers

- PSAD is useful for predicting reclassification of prostate cancer patients eligible for active surveillance

Takahiro Inoue (Kyoto University)

- Surveillance policy for patients with stage I testicular germ cell cancer in the multi-detector computed tomography era

Takeshi Yuasa (Cancer Institute Hospital)

- Reassessment of risk factors for biochemical recurrence in intermediate-risk prostate cancer treated with radical prostatectomy

Shintaro Narita (Akita University)

- An analysis of PSA recurrence-free survival by therapy in localized prostate cancer

Atsushi Takamoto (Okayama University)

- Long-term outcomes of prostate brachytherapy in Japan **【Best Presentation】**

Yasuto Yagi (Tokyo Medical Center)

Renal and urothelial cancers

- Different clinicopathological features between patients who developed early and late recurrence following surgery for renal cell carcinoma

Yoichi Fujii (Toranomom Hospital)

- Prognostic classification of clear cell renal cell carcinoma by gene expression profiling using DNA microarray

Tomohiko Yanagida (Fukushima Medical University)

- Intravesical seeding of upper urinary tract urothelial carcinoma cells

Akihiro Ito (Tohoku Univ.)

- Gemcitabine-docetaxel-carboplatin as second-line chemotherapy in patients with advanced urothelial carcinoma for whom gemcitabine-cisplatin chemotherapy has failed

Akitoshi Fukatsu (Komaki City Hospital)

- Therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma

Satoshi Noda (Shiga Univ. of Medical Science Hospital)

- Efficacy of high-slip skin care pad on sorafenib-induced hand-foot skin reaction

Nobuo Shinohara (Hokkaido university)

- Randomized phase III trial of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin (MVAC) followed by radical cystectomy compared with RC alone for muscle-invasive bladder cancer : Japan Clinical Oncology Group study, JCOG020

Kiyohide Fujimoto (Nara Medical University)

- Galectin 9 and PINCH, novel immunotherapy targets of renal cell carcinoma

Hidenori Kawashima (Osaka City University)

Endocrine cancer

- Iodine-131 Therapy in Cases with Metastatic Well-differentiated Thyroid Cancer

Katsuyuki Karasawa (Tokyo Metropolitan Cancer and Infectious diseases Center
Komagome Hospital)

Sarcomas of the soft tissues and bone

- Identification of miR-34a as a prognostic factor and possible therapeutic target for

Ewing's sarcoma

F. Nakatani (National Cancer Center Hospital)

Leukemia, multiple myeloma and lymphoma

- Risk factors that predict herpes virus infections in patients with malignant lymphoma receiving conventional chemotherapy

Hiroto Tanaka (Nippon Medical School Hospital)

Supportive care and quality of life

- Nation-wide Questionnaire Study of Cancer Chemotherapy-induced Anemia and Blood Transfusion in Japan **【Best Presentation】**

Ichiro Yoshino (Japan Society of Clinical Oncology)

- PALO vs GRA for preventing CINV in HEC:A randomized,double-blind,phaseIII trial **【Best Presentation】**

Yuki Kogure (Shikoku Cancer Center)

- Effects of Palonosetron + Dexamethasone(day1) in the prevention of CINV induced by non-AC MEC.

Y. Sato (Hokkaido Cancer Center)

- Active palliation and new treatment strategies for malignant ascites using KM-CART

Keisuke Matsusaki (Kanamecho Hospital)

- A Study of Self-care Support for Oral Health Care of Chemotherapy Treated Patient

Aki Matsumaru (Hakodate Municipal Hospital)

Medical service collaborations among local institutions

- Hospital-pharmacy cooperation for patients treated with S-1 based chemotherapy.

Chisato Yamada (Aichi Cancer Center Hospital)

Occupational exposure to antineoplastic agents

- Environmental exposure to anticancer drugs in outpatient chemotherapy center

Hisako Sato (Kitasato Univ. Hospital)